Overview

* SINTX ( SINT ) Q3 revenue of $0.2 mln missed analyst expectations

* Operating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mln

* Company strengthened liquidity with $4.3 mln raised through warrant exercises

Outlook

* SINTX ( SINT ) plans to launch the SINAPTIC wedge system in the near term

* Company aims to expand clinical engagement in targeted surgical specialties

* SINTX ( SINT ) intends to leverage material science for polymer composites in implants

Result Drivers

* FIRST PRODUCT REVENUE - Recorded initial revenue from OsseoSculpt, a private-labeled orthobiologic product

* FACILITY OPTIMIZATION - Subleased Armor facility, saving up to $950,000 in lease costs

* STRENGTHENED LIQUIDITY - Raised $4.3 mln through warrant inducement and exercises

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $200,000 $400,000

Revenue (1

Analyst)

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for SINTX Technologies Inc ( SINT ) is $25.00, about 86.3% above its November 12 closing price of $3.43

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)